• JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
 
  Bookmark and Share
 
 
Doctoral Thesis
DOI
https://doi.org/10.11606/T.9.2020.tde-20022020-113820
Document
Author
Full name
Renata Luise de Araujo
E-mail
Institute/School/College
Knowledge Area
Date of Defense
Published
São Paulo, 2019
Supervisor
Committee
Genovese, Maria Ines (President)
Mancini Filho, Jorge
Santos, Rosa Ferreira dos
Sinnecker, Patricia
Title in Portuguese
Biodisponibilidade dos compostos fenólicos de Eugenia dysenterica DC e efeito sobre as respostas glicêmica, insulinêmica e incretínica de indivíduos portadores de síndrome metabólica e disglicemia
Keywords in Portuguese
Biodisponibilidade
Cagaita
Elagitaninos
Hiperglicemia pós-prandial
Abstract in Portuguese
A cagaita (Eugenia dysenterica DC), pertencente à família das mirtáceas, é um fruto nativo do bioma Cerrado, rico em compostos bioativos fenólicos (CBF) que estão associados a diversos efeitos biológicos benéficos à saúde humana, tais como redução da resistência à insulina e inflamação sistêmica. Os objetivos deste trabalho foram caracterizar quimicamente os compostos fenólicos presentes na cagaita, em especial os elagitaninos (ET), avaliar a biodisponibilidade dos ET presentes no suco de cagaita em seres humanos saudáveis e o seu efeito sobre as respostas glicêmica, insulinêmica e incretínica em indivíduos disglicêmicos, portadores de síndrome metabólica. A caracterização química dos CBF da cagaita foi realizada através de cromatografia líquida de ultra eficiência com ionização por eletrospray acoplada a detector de massas de alta resolução quadrupolo-tempo de vôo (CLUE-ESI-QTOF) e mostrou, de maneira inédita, a presença de elagitaninos como telimagrandina I e pedunculagina, além de derivados de ácido elágico, derivados de quercetina e derivados de miricetina. A biodisponibilidade dos ET da cagaita foi avaliada, após a administração do fruto na forma de suco a indivíduos saudáveis (n=16), por cromatografia líquida de alta eficiência acoplada a espectrômetro de massas com analisador quadrupolo simples (CLAE-DAD-ESI-Q(MS)) e CLUE-ESI-QTOF. Foi possível observar pela primeira vez a metabolização destes compostos (ET) do fruto com a identificação dos metabotipos A (37%), metabotipos B (44%) e metabotipos 0 (19%). Quanto às respostas endócrinas, em voluntários disglicêmicos portadores de síndrome metabólica (n=12) observou-se a área abaixo da curva (AUC) de glicose reduzida em 53%, insulina 38%, GIP (polipeptídeo insulinotrópico dependente de glicose) 78% e peptídeo-C 58% (p<0,05), em relação ao controle. No entanto, os hormônios GLP-1 (peptídeo-1 semelhante ao glucagon), glucagon e grelina não apresentaram diferença significativa em relação à AUC (p<0,05), em comparação ao controle. Também não foi observada diminuição significativa nas pressões sistólica e diastólica dos indivíduos estudados, comparando-se ao controle. Conclui-se, portanto, que o perfil de CBF da cagaita se destaca pela presença de ET, tais como telimagrandina I e pedunculagina, que são passíveis de metabolização, e o consumo do suco deste fruto é capaz de reduzir a glicemia pós-prandial em indivíduos disglicêmicos e portadores de síndrome metabólica.
Title in English
Bioavailability of phenolic compounds of Eugenia dysenterica DC and their effect on glycemic, insulinemic and incretinic responses in subject with metabolic syndrome and dysglycemia
Keywords in English
Bioavailability
Cagaita
Ellagitannins
Postprandial hyperglycemia
Abstract in English
Cagaita (Eugenia dysenterica DC) is a native fruit from Cerrado biome and belongs to Myrtaceae family. This fruit is rich in phenolic compounds, which are associated to human health benefits such as reduction of insulin resistance and systemic inflammation. The aim of this study was to characterize the phenolic composition of cagaita, specially in relation to ellagitannins (ET), to evaluate the bioavailability of ET present in cagaita juice in healthy subjects, and to evaluate the effect of cagaita juice on glycemic, insulinemic and incretinic responses in subjects with metabolic syndrome and dysglycemia. The chemical characterization of phenolic compounds was performed by ultra-performance liquid chromatography coupled to an accurate-mass quadrupole time-of-flight, with an electrospray ionization (ESI) system (UPLC-ESI-QTOF-MS/MS). The results showed, for the first time, the presence of ET such as tellimagrandin I, pedunculagin and galloyl-HHDP-hexoside, plus ellagic acid, quercetin and myricetin derivatives in cagaita fruit. The bioavailability of cagaita ET, after cagaita juice consumption by healthy subjects (n=16), was evaluated by high-performance liquid chromatography equipped with a photodiode-array detector and a single quadrupole (single Q) mass spectrometer (HPLC-DAD-ESI-Q (MS)) and UPLC-ESI-QTOF-MS/MS. It was observed, for the first time, the metabolization of cagaita ET to urolithin and volunteers were classified as metabotype A (37%), urolithin metabotype B (44%) e urolithin metabotype 0 (19%). In relation to the endocrine responses, subjects with metabolic syndrome and dysglycemia (n=12) showed reduction of area under the curve (AUC) of glucose in 53%, insulin in 38%, GIP (glucose-dependent insulinotropic polypeptide) in 78% and C-peptide in 58% (p<0.05) after the consumption of cagaita juice along with bread. However, GLP-1 (glucagon-like peptide-1), glucagon and ghrelin were not affected by cagaita juice ingestion. There was no significant decrease in systolic and diastolic blood pressure, after cagaita juice consumption (p<0.05). In conclusion, the phenolic profile of cagaita stands out by the presence of ET, such as tellimagrandin I and pedunculagin and galloyl-HHDP-hexoside. These compounds can be metabolized into urolithins and the consumption of cagaita juice is able to reduce postprandial glycemia in dysglycemic subjects.
 
WARNING - Viewing this document is conditioned on your acceptance of the following terms of use:
This document is only for private use for research and teaching activities. Reproduction for commercial use is forbidden. This rights cover the whole data about this document as well as its contents. Any uses or copies of this document in whole or in part must include the author's name.
There are withheld file due to requirements (data publishing, patents or rights).
Release Date
2022-02-19
Publishing Date
2020-02-28
 
WARNING: Learn what derived works are clicking here.
All rights of the thesis/dissertation are from the authors
CeTI-SC/STI
Digital Library of Theses and Dissertations of USP. Copyright © 2001-2021. All rights reserved.